Retrieve available abstracts of 45 articles: HTML format
Single Articles
June 2025
AIZAWA R, Ogata T, Goto T, Otani T, et al Clinical Outcomes of Metastasis-directed Therapy for Oligo-metastatic Prostate
Cancer Diagnosed Using PSMA-PET/CT or Whole-body MRI.
Anticancer Res. 2025;45:2515-2525. PubMedAbstract available
NGUYEN MD, Gorobets O, Djoua YJ, Rose-Dite-Modestine J, et al End-of-life Androgen Deprivation Syndrome With Enzalutamide in Metastatic
Prostate Cancer: A Case Report.
Anticancer Res. 2025;45:2535-2538. PubMedAbstract available
May 2025
TAKASHIMA Y, Yoshii K, Tanaka M, Tashiro K, et al Ubiquitin-proteasome Pathway-linked Gene Signatures as Prognostic Indicators in
Prostate Cancer.
Anticancer Res. 2025;45:1825-1841. PubMedAbstract available
AOKI M, Matsui H, Kurihara S, Ohtake N, et al Comparison of BRCA2 Single Nucleotide Variants Between Japanese Patients With
Familial Prostate Cancer, Sporadic Prostate Cancer, and Benign Prostatic
Hyperplasia.
Anticancer Res. 2025;45:2195-2204. PubMedAbstract available
April 2025
NAKAI Y, Onishi K, Nakahama T, Kagebayashi Y, et al Evaluation of Candidates for Upfront Docetaxel Therapy Among Patients With
Metastatic Castration-sensitive Prostate Cancer from a Retrospective Multicenter
Study (MAHOROBA study).
Anticancer Res. 2025;45:1653-1660. PubMedAbstract available
March 2025
HIRATA J, Hara T, Jimbo N, Ueki H, et al Genomic Profiling of Small Cell Neuroendocrine Prostate Cancer and its
Implications for Targeted Therapies.
Anticancer Res. 2025;45:1137-1147. PubMedAbstract available
HSU JY, Ou HC, Ou YC, Lin YS, et al Safety and Outcomes of Intraoperative Ventriculoperitoneal Shunt Clamping During
Robotic-assisted Radical Prostatectomy: Retrospective Cohort Analysis.
Anticancer Res. 2025;45:1281-1289. PubMedAbstract available
NIEDER C, Haukland EC, Stanisavljevic L, Mannsaker B, et al Radiotherapy for Bone Metastases in Patients With Excellent Performance Status:
Patterns of Care and Prognostic Factors for Survival.
Anticancer Res. 2025;45:1149-1158. PubMedAbstract available
WU J, Lagunas AM, Crowe DL DNA Ligase 4 Inhibition Sensitizes Prostate Cancer to Immune Checkpoint Blockade
In Vivo.
Anticancer Res. 2025;45:883-896. PubMedAbstract available
February 2025
RADES D, Kristiansen C, Vestergaard Madsen C, Kuter JD, et al Bladder Volume <200 ml During a Course of Moderate Hypofractionated Irradiation
in Patients With Localized Prostate Cancer.
Anticancer Res. 2025;45:701-708. PubMedAbstract available
HIROSHIGE T, Suekane H, Tokunaga T, Uegaki M, et al Prognostic Stratification Using Early Prostate-specific Antigen Kinetics in Men
With Metastatic Hormone-sensitive Prostate Cancer.
Anticancer Res. 2025;45:751-759. PubMedAbstract available
December 2024
YIN W, He P, Zou Z, Lin J, et al SLC15A2 Serves as a Novel Prognostic Biomarker and Target for Prostate Cancer.
Anticancer Res. 2024;45:153-172. PubMedAbstract available
KAMIMA T, Ueda Y, Fukunaga JI, Shimizu Y, et al Enhancing Estimation Accuracy of Prostate Cancer VMAT Planning: A Knowledge-based
Approach Using Multiple Collimator Angles.
Anticancer Res. 2024;44:5303-5312. PubMedAbstract available
October 2024
RADES D, Cremers F, Ziemann C, Splettstosser L, et al Changes in Bladder Volume During Radiotherapy for Prostate Cancer.
Anticancer Res. 2024;44:4457-4463. PubMedAbstract available
POULSEN TS, Lorup AN, Kongsted P, Eefsen RL, et al TMPRSS2:ERG Gene Fusion Might Predict Resistance to PARP Inhibitors in Metastatic
Castration-resistant Prostate Cancer.
Anticancer Res. 2024;44:4203-4211. PubMedAbstract available
September 2024
SATO M, Sato T, Hozumi C, Han Q, et al [(11)C]Methionine PET vs. [(18)F]Fluorodeoxyglucose PET Whole-body Imaging to
Determine the Extent of Methionine-addiction Compared to Glucose-addiction of
Primary and Metastatic Cancer of the Trunk in Patients.
Anticancer Res. 2024;44:3891-3898. PubMedAbstract available
August 2024
PICKETT C, Karunanandaa K, Stackable K, Eaton DB Jr, et al Prescription Medications and Overall Survival in Metastatic Hormone Sensitive
Prostate Cancer.
Anticancer Res. 2024;44:3443-3449. PubMedAbstract available
July 2024
KUSTER JHS, Erb HHH, Ahrend H, Abazid A, et al Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic
Drugs Abiraterone, Cabazitaxel, Docetaxel and Enzalutamide.
Anticancer Res. 2024;44:2815-2821. PubMedAbstract available
MITSUNARI K, Fukushima H, Kurata H, Harada J, et al Predictive Factors for Early Biochemical Recurrence Following Robot-assisted
Radical Prostatectomy: The Impact of PSA Level, Gleason Score, and Pathological
Tumor Stage.
Anticancer Res. 2024;44:3149-3154. PubMedAbstract available
YAMAMOTO Y, Nishimoto M, Akashi Y, Kiba K, et al Impact of Novel Agents on Patient Characteristics, Treatment Patterns, and
Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer.
Anticancer Res. 2024;44:3155-3161. PubMedAbstract available
HAN S, Jang S, Lee SW, Kim HY, et al hMAGEA2 Accelerates the Progression of Prostate Cancer via the EFNA3-Erk1/2
Signaling Pathway.
Anticancer Res. 2024;44:2847-2859. PubMedAbstract available
June 2024
WAKITA N, Hara T, Suzuki K, Terakawa T, et al Efficacy of Combination Therapy With Radium-223 and Enzalutamide in
Castration-resistant Prostate Cancer With Bone Metastases.
Anticancer Res. 2024;44:2627-2635. PubMedAbstract available
WAIBEL S, Graf N, Storz J, Schultze-Seemann S, et al Photoimmunotherapy of Prostate Cancer With Antibody and Fab Fragments Targeting
the Prostate Specific Membrane Antigen.
Anticancer Res. 2024;44:2343-2348. PubMedAbstract available
WANG YJ, Hao YY, Lee DH, Guo XY, et al Hispidin Increases Cell Apoptosis and Ferroptosis in Prostate Cancer Cells
Through Phosphatidylinositol-3-Kinase and Mitogen-activated Protein Kinase
Signaling Pathway.
Anticancer Res. 2024;44:2533-2544. PubMedAbstract available
May 2024
TAMBURO M, Buffettino E, Pepe P, Marletta G, et al Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.
Anticancer Res. 2024;44:2205-2210. PubMedAbstract available
April 2024
MASUDA H, Amemiya Y, Yagisawa N, Arai T, et al Association Between Acute Kidney Injury and the Trendelenburg Position Angle
During Robot-assisted Radical Prostatectomy.
Anticancer Res. 2024;44:1767-1772. PubMedAbstract available
KASHIWAGI E, Kawahara T, Kinoshita F, Shiota M, et al The Role of Adipocytokines and their Receptors in Prostate Cancer: Adiponectin
May Protect Against Progression.
Anticancer Res. 2024;44:1369-1376. PubMedAbstract available
CHANG CC, Chiou JK, Lin CJ, Lu K, et al Machine-learning Algorithm-based Risk Prediction and Screening-detected Prostate
Cancer in A Benign Prostate Hyperplasia Cohort.
Anticancer Res. 2024;44:1683-1693. PubMedAbstract available
March 2024
HOLM I, Hernroth B, Rosander A, Tassidis H, et al Manganese as a Possible Anticancer Enhancer in Docetaxel Treatment of Prostate
Cancer Cells.
Anticancer Res. 2024;44:953-962. PubMedAbstract available
YAMAMICHI G, Kato T, Watabe T, Hatano K, et al Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand
Therapy in Prostate Cancer.
Anticancer Res. 2024;44:879-888. PubMedAbstract available
HERNANDEZ-VALENCIA CG, Rodriguez-Martinez G, Carriles-Perez AM, Gonzalez-Perez D, et al Antiproliferative and Antimigratory Activity of Poly-gallic Acid in Cancer Cell
Lines.
Anticancer Res. 2024;44:1201-1208. PubMedAbstract available
February 2024
DELL'ATTI L Biparametric MRI for Local Staging of Prostate Cancer: Current Status and Future
Applications.
Anticancer Res. 2024;44:463-470. PubMedAbstract available
KUROKAWA G, Mori K, Sasaki H, Nakano J, et al Effectiveness of Magnetic Resonance Imaging/Ultrasound-guided Target Biopsy in
Detecting Clinically Significant Prostate Cancer.
Anticancer Res. 2024;44:679-686. PubMedAbstract available
SAKAMOTO S, Ando K, Pae S, Zhao X, et al Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese
Castration-resistant Prostate Cancer.
Anticancer Res. 2024;44:639-647. PubMedAbstract available
January 2024
OKA D, Sekine Y, Tsuji Y, Nakayama H, et al Simvastatin Enhances the Radiosensitivity of Androgen-independent Prostate Cancer
Cells via Inhibition of RAD51 Expression.
Anticancer Res. 2024;44:93-98. PubMedAbstract available
REINIKAINEN P, Lehtinen I, Luukkaala T, Kellokumpu-Lehtinen PL, et al Safer and More Convenient Modern Curative Radiotherapy for Patients With Early
Prostate Cancer.
Anticancer Res. 2024;44:139-150. PubMedAbstract available
December 2023
MIYAZAWA Y, Sekine Y, Oka D, Nakazawa S, et al Simvastatin Induces Autophagy and Inhibits Proliferation in Prostate Cancer
Cells.
Anticancer Res. 2023;43:5377-5386. PubMedAbstract available
MAEDA-MINAMI A, Nishikawa T, Ishikawa H, Mutoh M, et al Angiotensin II Receptor Blockers Cause Changes in Prostate-specific Antigen
Levels: A Retrospective Cohort Study.
Anticancer Res. 2023;43:5629-5636. PubMedAbstract available
FUKUI Y, Yamada Y, Sakamoto S, Horikoshi T, et al Preoperative PI-RADS v2.1 Scoring System Improves Risk Classification in Patients
Undergoing Radical Prostatectomy.
Anticancer Res. 2023;43:5705-5712. PubMedAbstract available
SMULDERS-SRINIVASAN TK, Jenkinson SE, Brown LJ, Lenis VP, et al PDIA6 and Maspin in Prostate Cancer.
Anticancer Res. 2023;43:5331-5340. PubMedAbstract available
November 2023
YAMAMOTO T, Umezawa R, Shimada S, Takahashi N, et al The Impact of Pathological Grade Group 3 on Relapse-free Survival After Salvage
Radiotherapy for Postoperative Prostate Cancer.
Anticancer Res. 2023;43:5115-5125. PubMedAbstract available
October 2023
KANO H, Izumi K, Nakagawa R, Toriumi R, et al Role of Positive Biopsy Core Ratio in Prostate Cancer Patients.
Anticancer Res. 2023;43:4619-4626. PubMedAbstract available
NAGATA Y, Jojima K, Matsukawa T, Tomisaki I, et al Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line
Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
Anticancer Res. 2023;43:4573-4581. PubMedAbstract available
KUSUHARA Y, Fukawa T, Fukumori T, Ueno Y, et al Effect of Positive Biopsy Core Rate on Low-dose-rate Brachytherapy Outcomes in
Intermediate-risk Prostate Cancer.
Anticancer Res. 2023;43:4627-4635. PubMedAbstract available
URABE F, Kobayashi D, Iwatani K, Imai YU, et al The Efficacy and Safety of a Low Relative Dose Intensity of Cabazitaxel in
Patients With Metastatic Castration-resistant Prostate Cancer.
Anticancer Res. 2023;43:4611-4617. PubMedAbstract available